AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24360050
Drug: Dexmedetomidine (Dex)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (Dex) 0.3 µg/kg intravenously for initial bolus (duration 15 min) and then 0.3 µg·kg(‐1)·h(‐1) continuous infusion
Trial: 24360050
Drug: Dexmedetomidine (Dex)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (Dex) 0.5 µg/kg intravenously (duration 15 min) for initial load and then 0.3 µg·kg(‐1)·h(‐1) continuous infusion
Trial: 12759560
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg triazolam (TRZ)
Trial: 3510286
Drug: Dexamethasone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (50 mg IV bolus on admission, then 100 mg on Days 1, 2, and 3, 50 mg on Day 4, and 25 mg on Day 5 on continuous IV infusion)
Trial: 26882043
Drug: VTP-27999 (75-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VTP-27999 (75-600 mg)
Trial: 22313154
Drug: saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saxagliptin 5 mg once daily for 24 weeks
Trial: 17563091
Drug: Current use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current use of long-acting benzodiazepines (restricted to subjects with four or less prescriptions filled in the previous year)
Trial: 16154346
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of ephedrine 30 mg in 1 L of 0.9% saline after spinal block, titrated to maternal systolic pressure.
Trial: 16154346
Drug: 1 L
RxNorm normalized name: BLUE 1 LAKE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L 0.9% saline before spinal block (control group).
Trial: 12012141
Drug: Topotecan alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan alone (1.5 mg/m² for 5 days)
Trial: 12012141
Drug: Topotecan with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan with amifostine (300 mg/m² prior to topotecan)
Trial: 1486827
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg Zopiclone
Trial: 22453200
Drug: Progesterone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (300 mg daily at bedtime)
Trial: 18027874
Drug: Terlipressin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (2 mg injection)
Trial: 12456421
Drug: Ketamine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (various doses)
Trial: 2344010
Drug: Bromocriptine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine treatment for four months
Trial: 21525141
Drug: Dioctahedral smectite
RxNorm normalized name: Dioctahedral smectite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dioctahedral smectite (DS) 1.5 g thrice daily for 5 days
Trial: 17845320
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate for maximum of 48 h
Trial: 21262883
Drug: NIPPV (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIPPV (in infants who received surfactant therapy)
Trial: 15100715
Drug: High-protein, high-sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein, high-sodium diet (90 g protein/day, 180 mmol sodium/day)
Trial: 15100715
Drug: Moderate-protein, low-sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-protein, low-sodium diet (70 g protein/day, 65 mmol sodium/day)
Trial: 8348277
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg of i.m. depot methylprednisolone acetate (MPA)
Trial: 8348277
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg methylprednisolone (MP) orally
Trial: 2883004
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine JNIH‐6
Trial: 2883004
Drug: Placebo (carrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (carrier solution of aluminium phosphate)
Trial: 29751193
Drug: High added
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High added sugar low fiber diet (HASLF; 25% total energy from AS and 8.2 g/1000 kcal)
Trial: 20417426
Drug: Conventional hysteroscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional hysteroscopy with saline solution
Trial: 12872556
Drug: Mupirocin treatment
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin treatment (n = 96)
Trial: 8537688
Drug: Pyrimethamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrimethamine (50 mg) with folinic acid (15 mg) given three times weekly
Trial: 1907074
Drug: Thyrotropin-releasing hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin-releasing hormone (200 micrograms intravenous)
Trial: 1907074
Drug: Thyrotropin-releasing hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin-releasing hormone (400 micrograms intravenous)
Trial: 9290464
Drug: Thyrotropin-releasing hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin-releasing hormone
Trial: 7051244
Drug: Trimethoprim (TMP)
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimethoprim (TMP) 320 mg plus Sulfamethoxazole (SMZ) 1,600 mg daily for 14 days
Trial: 7051244
Drug: Ampicillin 2
RxNorm normalized name: ampicillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin 2 g daily for 14 days
Trial: 30496879
Drug: Dose differences
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose differences between dCT and CT treatment plans
Trial: 21417591
Drug: Air-abrasive treatment
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air-abrasive treatment
Trial: 1965344
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no calcium entry blocker)
Trial: 20605604
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg of ropivacaine (group I)
Trial: 2977392
Drug: Acitretin administered
RxNorm normalized name: Acitretin
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acitretin administered with food (moderate breakfast)
Trial: 2977392
Drug: Acitretin administered
RxNorm normalized name: Acitretin
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acitretin administered during a complete fast
Trial: 23540442
Drug: CsA 5
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA 5 mg/kg continuous infusion over 24 hours
Trial: 14595084
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of OROS methylphenidate HCL (MPH)
Trial: 10898926
Drug: Bromperidol at
RxNorm normalized name: bromperidol
DrugBank: Bromperidol (DB12401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromperidol at 6 or 12 or 18 mg/day for 3 weeks
Trial: 6611585
Drug: Urea (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea (1.0 g/kg b.w.)
Trial: 26362090
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) with short-course androgen deprivation therapy (ADT) (4 months of GnRH agonist therapy and antiandrogen)
Trial: 8311085
Drug: Low-dose cyclosporine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporine (≤5 mg/kg/d)
Trial: 8311085
Drug: Second biopsy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second biopsy after further 18 months of therapy
Trial: 3582481
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg o.d.)
Trial: 31648099
Drug: Patritumab +
RxNorm normalized name: Patritumab
DrugBank: Patritumab (DB12090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patritumab + cetuximab + platinum therapy
Trial: 31648099
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + cetuximab + platinum therapy
Trial: 28950289
Drug: Glycoengineered imgatuzumab
RxNorm normalized name: Imgatuzumab
DrugBank: Imgatuzumab (DB14884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoengineered imgatuzumab (GA201; 700 mg)
Trial: 28950289
Drug: Both antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both antibodies
Trial: 23883812
Drug: Pollen blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pollen blocker cream applied three times daily for 30 days
Trial: 22796122
Drug: Plant sterol/stanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol/stanol softgel capsules (1.8 g/d)
Trial: 10877012
Drug: Rofecoxib 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 100 mg
Trial: 9126665
Drug: Testosterone-enanthate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone-enanthate (200 mg/week intramuscularly)
Trial: 9126665
Drug: Testolactone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testolactone (1 g/day orally)
Trial: 9126665
Drug: Testosterone-enanthate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone-enanthate (200 mg/week) + Testolactone (1 g/day)
Trial: 8243792
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day cyclobenzaprine at bedtime
Trial: 31923712
Drug: Whole Pelvic
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole Pelvic Radiation Therapy (WPRT)
Trial: 20678219
Drug: Individual written
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual written prescription for exercise (Control)
Trial: 2418400
Drug: 5‐fluorouracil (B‐CMF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (B‐CMF) chemotherapy prior to and two courses after standard therapy
Trial: 2418400
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (preoperative irradiation followed by radical surgery)
Trial: 27310254
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg daily valganciclovir (group 1)
Trial: 27310254
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg daily valganciclovir (group 2)
Trial: 22594981
Drug: Topical photodynamic
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical photodynamic therapy using methylene blue and Hypericum perforatum extract
Trial: 15832335
Drug: High exposure
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High exposure condition (0.63 W/kg 1 g averaged SAR)
Trial: 12887472
Drug: Triptorelin 3.75
RxNorm normalized name: triptorelin 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin 3.75 mg
Trial: 19035858
Drug: Leuprolide 7.5
RxNorm normalized name: leuprolide 7.5 mg/month intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide 7.5 mg
Trial: 7201905
Drug: Cisplatin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (60 mg/m2 IV) administered in the morning (6:00 A.M.)
Trial: 30635477
Drug: Placebo induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo induction followed by glatiramer acetate (GA) monotherapy
Trial: 28835387
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D and leucine-enriched whey protein medical nutrition drink (21 g leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D3)
Trial: 19507458
Drug: Intravenous zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zoledronic acid (ZO group)
Trial: 12456630
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral estrogen/progestin (n = 21)
Trial: 12456630
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral estrogen/intrauterine progestin (n = 22)
Trial: 1973085
Drug: Bromocriptine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (5 mg divided daily)
Trial: 1973085
Drug: Bromocriptine (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (5-10 mg)
Trial: 7213506
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily dosage (0.25 mg)
Trial: 7213506
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily dosage (0.125 mg)
Trial: 7213506
Drug: Four times
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four times daily dosage (0.0625 mg)
Trial: 7213506
Drug: All dosage
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dosage frequencies
Trial: 31182128
Drug: Med-Stress intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Med-Stress intervention (sequential enhancement of self-efficacy and perceived social support)
Trial: 31182128
Drug: Med-Stress intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Med-Stress intervention (sequential enhancement of perceived social support and self-efficacy)
Trial: 25841539
Drug: Synbiotic yogurt
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic yogurt (containing Streptococcus thermophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subspecies lactis (BB‐12) at 5 × 10(9) cfu/100 mL and 1 g of inulin)
Trial: 19741531
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin noradrenaline reuptake inhibitors
Trial: 6537445
Drug: Drug education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug education course
Trial: 30639756
Drug: Factors evaluated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors evaluated included age, sex, diagnosis, morning/evening assessment, modified Medical Research Council breathlessness score, morphine treatment
Trial: 11129615
Drug: Epidural PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural PCA with bupivacaine 0.125%, sufentanil 0.75 microgram/ml and epinephrine 1/800.000 with a basal rate of 3 ml/hr
Trial: 8750479
Drug: New anticancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New anticancer therapies
Trial: 1724541
Drug: Low-rate ANF
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-rate ANF infusion (0.25 micrograms/min)
Trial: 477026
Drug: Intramuscular immune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular immune serum globulin (ISG)
Trial: 477026
Drug: Intravenous modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous modified immune serum globulin (M‐ISG)
Trial: 25562479
Drug: Daily disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily disposable contact lenses (nelfilcon A, DAILIES AquaComfort Plus)
Trial: 20926751
Drug: Tonapofylline (0.2-375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonapofylline (0.2-375 mg)
Trial: 20926751
Drug: Tonapofylline (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonapofylline (single dose)
Trial: 17681360
Drug: GPO dihydroartemisinin
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GPO dihydroartemisinin tablet formulation, 200mg single oral dose
Trial: 17681360
Drug: Dafra dihydroartemisinin
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dafra dihydroartemisinin tablet formulation, 200mg single oral dose
Trial: 17681360
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of DHA (both formulations)
Trial: 17681360
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of DHA (both formulations)
Trial: 16649968
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (1 mg/kg i.m. every 4 weeks for 6 months) + Letrozole (2.5 mg/day orally for 12 months)
Trial: 16649968
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (1 mg/kg i.m. every 4 weeks for 6 months) + Placebo
Trial: 12562453
Drug: Omeprazole, 20
RxNorm normalized name: Omeprazole, 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 20 mg/day for 5 days with 3 mg budesonide controlled-release capsules on day 5
Trial: 2130823
Drug: Usual diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual diet (438 +/- 118 mg/day)
Trial: 28648880
Drug: Animated biofeedback
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animated biofeedback therapy
Trial: 28648880
Drug: Non-animated biofeedback
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-animated biofeedback therapy
Trial: 20526200
Drug: No use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No use of hormone therapy
Trial: 16104901
Drug: DN-101 (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DN-101 (high-dose oral calcitriol) combined with docetaxel
Trial: 10368039
Drug: Oxygen inhalation
RxNorm normalized name: oxygen INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen inhalation during radiotherapy sessions
Trial: 10368039
Drug: Oxygen inhalation
RxNorm normalized name: oxygen INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen inhalation during all radiotherapy sessions
Trial: 6109345
Drug: Tofisopam (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofisopam (100 mg single dose)
Trial: 6109345
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 mg single dose)
Trial: 6109345
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 mg) + Ethanol (0.8 g/kg)
Trial: 6109345
Drug: Tofisopam (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofisopam (100 + 50 + 50 + 100 mg repeated doses)
Trial: 27445468
Drug: UMEC/VI 62.5/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMEC/VI 62.5/25 µg
Trial: 8183178
Drug: Nasal salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal salmon calcitonin (SCT) (100 IU daily) plus oral calcium
Trial: 3963018
Drug: Flurbiprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (200 mg total daily dose, administered four times a day)
Trial: 3963018
Drug: Flurbiprofen (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (up to 300 mg per day)
Trial: 31137095
Drug: Group B1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B1 (sound therapy for normal to mild hearing loss)
Trial: 31137095
Drug: Group A2
RxNorm normalized name: PROCYANIDIN A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A2 (sound therapy for moderate to profound hearing loss)
Trial: 27895466
Drug: CKD‐519 (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD‐519 (25, 50, 100, 200, or 400 mg)
Trial: 15838760
Drug: Oral Sialogogum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Sialogogum
Trial: 28432193
Drug: Antimicrobial (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial (6 mg/kg gamithromycin)
Trial: 23505169
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day of IQP G‐002AS
Trial: 14503053
Drug: TCM group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM group (Chinese drug medication according to patients' syndrome differentiation)
Trial: 11768164
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg DHA
Trial: 11768164
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg DHA
Trial: 2962589
Drug: Phosphonoformate (PFA)
RxNorm normalized name: Phosphonoformic acid
DrugBank: Foscarnet (DB00529)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phosphonoformate (PFA) intravenous infusion
Trial: 26149448
Drug: Oral Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Chinese herbal formula (Pei Tu Qing Xin granules; PTQX)
Trial: 21677054
Drug: Lactating women
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactating women receiving no protein-energy supplements (control group for protein-energy trial)